Table 1 Characteristics of included studies
Author; Year | Country | Study years | Study design | Setting | CRs MIC /mg/L | Type of infection | Male/ Female | Age (years) | Treatment regimen | Sample size (PXs vs. Non-PXs) | Route of colistin | APACHE II score (mean) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polymyxins group | Non-polymyxins group | ||||||||||||
Trottier 2007 [27] | USA | 2004–05 | RS | MIX | NA | Mixb | 83/33 | 17 ~ 90 | COL | AMK; FEP; CPF; DOX; IMP; MNO; TZP | 96 vs. 20 | IV/IH/IV+ IH/IV + IT | NR |
Betrosian 2008 [20] | Greece | NA | RCT | ICU | NA | VAP | 14/14 | adult | COL | SAM | 15 vs. 13 | IV | 14 |
Lopez-Cortes 2014 [23] | Spain | 2010 | PS | NA | ≥32 | RT/SS/SST UT/IAI/CNS OA/Bm | NA | >18 | COL; COL+TGC; COL+CRs; COL+SUL; COL+AG; COL+RIF; COL+TGC + AG; COL+TGC+ CRs + AG | CRs; TGC; SUL; TCY; CRs + TGC; CRs + AG; TGC + RIF; TGC + AG; TGC + CRs + RIF | 52 vs. 12 | IV | NA |
Ozvatan 2016 [24] | Turkey | 1996–2010 | RS | NA | NA | VAP | NA | ≥18 | COL; COL+OTH | M/I; SAM; CSL; OTH | 29 vs. 187 | IV | NA |
Zalts 2016 [14] | Israel | 2008–09 | RS | ICU | NA | VAP | 70/28 | >18 | COL | SAM | 66 vs. 32 | IV | 17.5 |
Pan 2018 [25] | China | 2013–17 | RCS | NA | NA | ICI | 30/31 | >18 | PB+ CTR | M/I + AMK; M/I + TGC; M/I + CSL; M/I + TGC + CSL; CSL; CSL + AMK; | 23 vs. 38 | IV + IT | 18 |
Khalili 2018 [21] | Iran | 2015–17 | RCT | ICU | ≥0.08 | VAP | 35/12 | 18 ~ 75 | MEM + COL | MEM + SAM | 24 vs.23 | IV | NA |
Liang 2018 [22] | Taiwan | 2010–15 | RS | MIX | NA | Pmn | 167/71 | >20 | TGC + COL | TGC; TGC + OTH; SUL; SUL + OTH | 110 vs. 128 | IV/IV+ IH | 23 |
Sipahi 2018 [26] | Turkey & France | 2007–16 | RS | ICU | NA | Meg | 12/8 | >18 | TGC + COL | TGC + NET; TGC + AMK; TGC + MEM; TGC | 8 vs. 12 | IV/ IV + IT | NA |
Chusri 2019 [13] | Thailand | 2012–17 | RS | MIX | ≥16 | IAI | 16/12 | >18 | TGC + COL | TGC | 14 vs. 14 | IV | 15/median |
Raz-Pasteur 2019 [19] | Israel | 2013–15 | RCS | MIX | NA | Pmn/SST/Bm | 62/21 72/40 | Any | COL | SAM; TMP-SMX | 59 vs. 24 59 vs. 53 | IV | NA |